磁共振质子密度脂肪分数（MRI-PDFF）评估慢性HBV感染者肝脂肪变性及分布特点

王丽旻; 包超; 赵凯越; 靳婕华; 郑卓肇; 黄缘

doi:10.12449/JCH240511

磁共振质子密度脂肪分数（MRI-PDFF）评估慢性HBV感染者肝脂肪变性及分布特点

DOI: 10.12449/JCH240511

王丽旻^a,
包超^b,
赵凯越^a,
靳婕华^a,
郑卓肇^b,
黄缘^a, , ,

a.
清华大学附属北京清华长庚医院消化内科，北京 102218
b.
清华大学附属北京清华长庚医院放射诊断科，北京 102218

基金项目:

北京市自然科学基金 (7202240);

清华大学自主科研项目 (2022PY002)

伦理学声明： 本研究方案于2021年5月26日经由北京清华长庚医院伦理委员会审批，批号：21228-0-01，所纳入患者均签署知情同意书。

利益冲突声明：本文不存在任何利益冲突。

作者贡献声明：王丽旻负责课题设计，资料分析，撰写论文；包超、赵凯越、靳婕华参与收集数据；黄缘、郑卓肇负责拟定写作思路，指导撰写文章并最后定稿。

详细信息

通信作者:
黄缘， huangy9815@163. com （ORCID： 0000-0003-1392-4619）

计量
- 文章访问数: 378
- HTML全文浏览量: 134
- PDF下载量: 46
- 被引次数: 0
出版历程
- 收稿日期: 2023-07-27
- 录用日期: 2023-09-05
- 出版日期: 2024-05-25

Value of magnetic resonance imaging-proton density fat fraction in evaluating the degree and distribution characteristics of hepatic steatosis in patients with chronic hepatitis B virus infection

a.
Department of Gastroenterology, Beijing Tsinghua Changgung Hospital，Tsinghua University，Beijing 102218，China
b.
Department of Radiological Diagnosis，Beijing Tsinghua Changgung Hospital，Tsinghua University，Beijing 102218，China

Research funding:

Beijing Natural Science Foundation (7202240);

Tsinghua University Independent Research (2022PY002)

More Information

Corresponding author: HUANG Yuan， huangy9815@163.com （ORCID： 0000-0003-1392-4619）

摘要

摘要: 目的利用磁共振质子密度脂肪分数（MRI-PDFF）评估慢性HBV感染者的肝脂肪变性的程度。方法选择北京清华长庚医院2018年1月—2022年12月门诊或者住院，明确诊断为慢性HBV感染，年龄>16岁的患者。所有患者均在本院行肝脏磁共振检查。依据是否合并肝硬化进行分组，比较患者的各个肝段PDFF值的一致性。使用Kappa一致性检验、组内相关系数（ICC）进行一致性分析。结果纳入76例核苷（酸）类似物经治患者，其中30.26%（23例）合并肝硬化，所有患者的MRI-PDFF算术均值波动在1.49%～30.93%，依据MRI-PDFF≥5%诊断为脂肪肝，38.16%（29例）患者合并脂肪肝。76例患者的全肝PDFF算术均值低于全肝PDFF加权均值，全肝PDFF加权均值、全肝PDFF算术均值、左半肝及右半肝的PDFF算术均值比较，差异无统计学意义（F=0.39，P=0.76）。各个肝段、左/右半肝PDFF算术均值与全肝PDFF加权均值、全肝PDFF算术均值的一致性较强（ICC均>0.75），但右半肝PDFF算术均值与全肝PDFF加权均值的一致性高于左半肝。合并肝硬化组患者在区分脂肪肝诊断的一致性检验方面，Ⅶ段PDFF算术均值与全肝PDFF加权均值一致性差（Kappa=0.39），左半肝、Ⅰ、Ⅱ、Ⅲ、Ⅴ、Ⅵ、Ⅷ为中等一致。合并肝硬化的患者Ⅶ段PDFF算术均值与全肝PDFF加权均值一致性最低，Ⅳ段一致性最高。未合并肝硬化的患者Ⅱ段PDFF算术均值与全肝PDFF加权均值一致性最低，Ⅴ段的一致性最高。结论 MRI-PDFF评估慢性HBV感染者的肝脂肪变性更全面，合并肝硬化的患者各肝段PDFF算术均值与全肝PDFF加权均值的一致性差异大。
- 乙型肝炎病毒 /
- 脂肪肝 /
- 磁共振成像
Abstract: Objective To investigate the value of magnetic resonance imaging-proton density fat fraction （MRI-PDFF） in evaluating hepatic steatosis in patients with chronic hepatitis B virus （HBV） infection. Methods The patients， aged >16 years， who visited the outpatient service or were hospitalized in Beijing Tsinghua Changgung Hospital from January 2018 to December 2022 and were diagnosed with chronic HBV infection were enrolled， and all patients underwent MRI examination of the liver in our hospital. The patients were divided into groups based on the presence or absence of liver cirrhosis， and the consistency in PDFF between different hepatic segments was compared between groups. The Kappa consistency test and intraclass correlation coefficient （ICC） were used for consistency analysis. Results A total of 76 patients treated with nucleoside analogues were enrolled， among whom 23 （30.26%） had liver cirrhosis. For all patients， the simple arithmetic average of PDFF fluctuated between 1.49% and 30.93%. According to MRI-PDFF ≥5% as the diagnostic criterion for fatty liver disease， there were 29 patients （38.16%） with fatty liver disease among all patients. For all 76 patients， the simple arithmetic average of PDFF was lower than the weighted average of PDFF for the whole liver， and there was no significant difference between the simple arithmetic average of PDFF， the weighted average of PDFF， and the PDFF values of the left and right lobes of the liver （F=0.39， P=0.76）. The consistency test showed that the PDFF values of each hepatic segment and the left and right lobes of the liver had strong consistency with the weighted average and simple arithmetic average of PDFF， with an ICC of >0.75， but the consistency between the PDFF value of the right lobe and the weighted average of PDFF was higher than that between the PDFF value of the left lobe and the weighted average of PDFF. In the consistency test of differentiating fatty liver disease in patients with liver cirrhosis， there was poor consistency between the PDFF value of segment Ⅶ and the weighted average of PDFF （Kappa=0.39）， with moderate consistency for the left lobe and the Ⅰ， Ⅱ， Ⅲ， Ⅴ， Ⅵ， and Ⅷ segments. For the patients with liver cirrhosis， the lowest consistency was observed between the PDFF value of Ⅶ segment and the weighted average of PDFF for the whole liver， and the highest consistency was observed between the PDFF value of Ⅵ segment and the weighted average of PDFF for the whole liver. For the patients without liver cirrhosis， the lowest consistency was observed between the PDFF value of Ⅱ segment and the weighted average of PDFF for the whole liver， and the highest consistency was observed between the PDFF value of Ⅴ segment and the weighted average of PDFF for the whole liver. Conclusion MRI-PDFF is more comprehensive in evaluating hepatic steatosis in patients with chronic HBV infection， and for the patients with liver cirrhosis， there is poor consistency between the PDFF value of each segment and the weighted average of PDFF.
- Hepatitis B virus /
- Fatty Liver /
- Magnetic Resonance Imaging

HTML全文

表 1 患者的临床特征

Table 1. Clinical characteristics of patients

项目	数值
性别［例（%）］
男	53（69.74）
女	23（30.26）
年龄（岁）	42（36～54）
BMI（kg/m²）	24.95±3.89
合并肝硬化［例（%）］	23（30.26）
受控衰减参数（dB/m）	262.36±36.72
MRI-PDFF（%）	6.89±5.32
LSM（kPa）	8.96±4.14
HBeAg阳性［例（%）］	28（36.84）
HBV DNA阳性［例（%）］	16（21.05）
ALT（U/L）	40.34±28.10
AST（U/L）	30.00±11.20
TBil（mmol/L）	15.11±11.50
Alb（g/L）	47.77±26.40
PLT（×10⁹/L）	211.86±77.61
TC（mmol/L）	4.63±2.11
TG（mmol/L）	1.71±0.82
LDL-C（mmol/L）	2.77±0.91

下载: 导出CSV

表 2 76例患者肝脏各部位的PDFF值

Table 2. PDFF of liver segments in 76 patients

项目	均值（%）	标准差（%）	最小值（%）	最大值（%）	P₂₅（%）	P₅₀（%）	P₇₅（%）
全肝加权	6.91	5.97	1.14	30.89	2.36	3.35	7.96
全肝	6.89	5.32	1.49	30.93	2.35	3.36	8.08
左半肝	6.29	5.53	0.81	30.71	1.93	3.11	8.27
右半肝	7.27	5.93	1.31	30.98	2.36	3.50	8.36
Ⅰ段	6.45	4.53	0.88	24.31	2.00	4.00	8.55
Ⅱ段	7.03	6.37	0.32	32.80	2.41	4.44	8.58
Ⅲ段	6.19	5.68	0.20	34.10	1.52	2.63	9.30
Ⅳ段	6.86	5.41	0.67	32.74	2.73	3.35	8.01
Ⅴ段	7.14	6.06	0.72	33.22	2.33	3.16	8.71
Ⅵ段	7.16	6.47	0.93	28.80	2.83	3.17	8.22
Ⅶ段	7.17	6.43	1.01	31.12	2.17	3.74	10.14
Ⅷ段	7.49	6.63	0.83	33.54	2.46	4.16	11.51
注：P₂₅，第25百分位数，P₅₀，中位数，P₇₅，第75百分位数。

下载: 导出CSV

表 3 各肝段、左/右半肝PDFF算术均值与全肝PDFF加权均值、全肝PDFF算术均值的一致性

Table 3. Consistency of arithmetic mean PDFF of each hepatic segment and left/right lobes of the liver with weighted mean PDFF of the whole liver and arithmetic mean PDFF of the whole liver

项目	全肝加权均值		全肝算术均值
项目	ICC值	P值	ICC值	P值
全肝加权均值	-		0.96	<0.01
全肝算术均值	0.96	<0.01	-
左半肝算术均值	0.97	<0.01	0.92	<0.01
右半肝算术均值	0.99	<0.01	0.98	<0.01
Ⅰ段算术均值	0.96	<0.01	0.92	<0.01
Ⅱ段算术均值	0.92	<0.01	0.97	<0.01
Ⅲ段算术均值	0.95	<0.01	0.91	<0.01
Ⅳ段算术均值	0.98	<0.01	0.98	<0.01
Ⅴ段算术均值	0.99	<0.01	0.99	<0.01
Ⅵ段算术均值	0.96	<0.01	0.97	<0.01
Ⅶ段算术均值	0.98	<0.01	0.98	<0.01
Ⅷ段算术均值	0.97	<0.01	0.96	<0.01

下载: 导出CSV

表 4 各肝段及全肝PDFF算术均值和全肝PDFF加权均值对肝脂肪变性诊断的一致性比较

Table 4. Comparison of the consistency of arithmetic mean PDFF of each hepatic segment and the whole liver and weighted mean PDFF of the whole liver in diagnosis of hepatic steatosis

项目	区分PDFF≥5%和<5%的Kappa值	P值
全肝	0.97	<0.01
左半肝	0.86	<0.01
右半肝	0.94	<0.01
Ⅰ段	0.89	<0.01
Ⅱ段	0.86	<0.01
Ⅲ段	0.88	<0.01
Ⅳ段	0.91	<0.01
Ⅴ段	0.91	<0.01
Ⅵ段	0.86	<0.01
Ⅶ段	0.88	<0.01
Ⅷ段	0.86	<0.01

下载: 导出CSV

表 5 合并肝硬化与未合并肝硬化全肝加权PDFF均值与各个肝段PDFF算术均值的一致性比较

Table 5. Comparison of the consistency of weighted mean PDFF of the whole liver and arithmetic mean PDFF of each hepatic segment in patients with and without liver cirrhosis

项目	合并肝硬化（n=23）				未合并肝硬化（n=53）
项目	ICC值	P值	Kappa值	P值	ICC值	P值	Kappa值	P值
左半肝	0.81	<0.01	0.56	<0.01	0.96	<0.01	0.87	<0.01
右半肝	0.88	<0.01	0.83	<0.01	0.99	<0.01	0.92	<0.01
Ⅰ段	0.78	<0.01	0.57	<0.01	0.97	<0.01	0.83	<0.01
Ⅱ段	0.76	<0.01	0.48	0.02	0.95	<0.01	0.75	<0.01
Ⅲ段	0.82	<0.01	0.65	<0.01	0.95	<0.01	0.79	<0.01
Ⅳ段	0.87	<0.01	0.83	<0.01	0.99	<0.01	0.87	<0.01
Ⅴ段	0.82	<0.01	0.65	<0.01	0.99	<0.01	0.92	<0.01
Ⅵ段	0.74	<0.01	0.48	<0.01	0.99	<0.01	0.83	<0.01
Ⅶ段	0.68	<0.01	0.39	0.03	0.99	<0.01	0.84	<0.01
Ⅷ段	0.76	<0.01	0.57	<0.01	0.98	<0.01	0.82	<0.01
注：ICC值，全肝PDFF加权均值与左半肝、右半肝、各个肝段PDFF算术均值的相关系数；Kappa值，区分PDFF≥5%和<5%的Kappa值。

下载: 导出CSV

参考文献(20)

[1]	KARLAS T, PETROFF D, SASSO M, et al. Individual patient data meta-analysis of controlled attenuation parameter(CAP) technology for assessing steatosis[J]. J Hepatol, 2017, 66( 5): 1022- 1030. DOI: 10.1016/j.jhep.2016.12.022.
[2]	SINGH S, ALLEN AM, WANG Z, et al. Fibrosis progression in nonalcoholic fatty liver vs nonalcoholic steatohepatitis: A systematic review and meta-analysis of paired-biopsy studies[J]. Clin Gastroenterol Hepatol, 2015, 13( 4): 643- 654. e1-9; quize39-40. DOI: 10.1016/j.cgh.2014.04.014.
[3]	LI J, YANG HI, YEH ML, et al. Association between fatty liver and cirrhosis, hepatocellular carcinoma, and hepatitis B surface antigen seroclearance in chronic hepatitis B[J]. J Infect Dis, 2021, 224( 2): 294- 302. DOI: 10.1093/infdis/jiaa739.
[4]	REEDER SB, CRUITE I, HAMILTON G, et al. Quantitative assessment of liver fat with magnetic resonance imaging and spectroscopy[J]. J Magn Reson Imaging, 2011, 34( 4): 729- 749. DOI: 10.1002/jmri.22775.
[5]	LE TA, CHEN J, CHANG C, et al. Effect of colesevelam on liver fat quantified by magnetic resonance in nonalcoholic steatohepatitis: a randomized controlled trial[J]. Hepatology, 2012, 56( 3): 922- 932. DOI: 10.1002/hep.25731.
[6]	LOOMBA R, SIRLIN CB, ANG B, et al. Ezetimibe for the treatment of nonalcoholic steatohepatitis: Assessment by novel magnetic resonance imaging and magnetic resonance elastography in a randomized trial(MOZART trial)[J]. Hepatology, 2015, 61( 4): 1239- 1250. DOI: 10.1002/hep.27647.
[7]	Chinese Medical Association, Chinese Society of Infectious Disease. Guidelines for the prevention and treatment of chronic hepatitis B(2022 version)[J]. Chin J Infect Dis, 2023, 41( 1): 3- 28. DOI: 10.3760/cma.j.cn311365-20230220-00050. 中华医学会肝病学分会, 中华医学会感染病学分会. 慢性乙型肝炎防治指南(2022年版)[J]. 中华传染病杂志, 2023, 41( 1): 3- 28. DOI: 10.3760/cma.j.cn311365-20230220-00050.
[8]	CAUSSY C, ALQUIRAISH MH, NGUYEN P, et al. Optimal threshold of controlled attenuation parameter with MRI-PDFF as the gold standard for the detection of hepatic steatosis[J]. Hepatology, 2018, 67( 4): 1348- 1359. DOI: 10.1002/hep.29639.
[9]	MISE Y, SATOU S, SHINDOH J, et al. Three-dimensional volumetry in 107 normal livers reveals clinically relevant inter-segment variation in size[J]. HPB, 2014, 16( 5): 439- 447. DOI: 10.1111/hpb.12157.
[10]	TOKUSHIGE K, IKEJIMA K, ONO M, et al. Evidence-based clinical practice guidelines for nonalcoholic fatty liver disease/nonalcoholic steatohepatitis 2020[J]. J Gastroenterol, 2021, 56( 11): 951- 963. DOI: 10.1007/s00535-021-01796-x.
[11]	TOKUSHIGE K, IKEJIMA K, ONO M, et al. Evidence-based clinical practice guidelines for nonalcoholic fatty liver disease/nonalcoholic steatohepatitis 2020[J]. J Gastroenterol, 2021, 56( 11): 951- 963. DOI: 10.1007/s00535-021-01796-x.
[12]	PARK CC, NGUYEN P, HERNANDEZ C, et al. Magnetic resonance elastography vs transient elastography in detection of fibrosis and noninvasive measurement of steatosis in patients with biopsy-proven nonalcoholic fatty liver disease[J]. Gastroenterology, 2017, 152( 3): 598- 607. e 2. DOI: 10.1053/j.gastro.2016.10.026.
[13]	HERNANDO D, SHARMA SD, ALIYARI GHASABEH M, et al. Multisite, multivendor validation of the accuracy and reproducibility of proton-density fat-fraction quantification at 1.5T and 3T using a fat-water phantom[J]. Magn Reson Med, 2017, 77( 4): 1516- 1524. DOI: 10.1002/mrm.26228.
[14]	VU KN, GILBERT G, CHALUT M, et al. MRI-determined liver proton density fat fraction, with MRS validation: Comparison of regions of interest sampling methods in patients with type 2 diabetes[J]. J Magn Reson Imaging, 2016, 43( 5): 1090- 1099. DOI: 10.1002/jmri.25083.
[15]	BONEKAMP S, TANG A, MASHHOOD A, et al. Spatial distribution of MRI-Determined hepatic proton density fat fraction in adults with nonalcoholic fatty liver disease[J]. J Magn Reson Imaging, 2014, 39( 6): 1525- 1532. DOI: 10.1002/jmri.24321.
[16]	KANG BK, KIM M, SONG SY, et al. Feasibility of modified Dixon MRI techniques for hepatic fat quantification in hepatic disorders: Validation with MRS and histology[J]. Br J Radiol, 2018, 91( 1089): 20170378. DOI: 10.1259/bjr.20170378.
[17]	ANAVI S, MADAR Z, TIROSH O. Non-alcoholic fatty liver disease, to struggle with the strangle: Oxygen availability in fatty livers[J]. Redox Biol, 2017, 13: 386- 392. DOI: 10.1016/j.redox.2017.06.008.
[18]	LI YT, CERCUEIL JP, YUAN J, et al. Liver intravoxel incoherent motion(IVIM) magnetic resonance imaging: A comprehensive review of published data on normal values and applications for fibrosis and tumor evaluation[J]. Quant Imaging Med Surg, 2017, 7( 1): 59- 78. DOI: 10.21037/qims.2017.02.03.
[19]	BOUDINAUD C, ABERGEL A, JOUBERT-ZAKEYH J, et al. Quantification of steatosis in alcoholic and nonalcoholic fatty liver disease: Evaluation of four MR techniques versus biopsy[J]. Eur J Radiol, 2019, 118: 169- 174. DOI: 10.1016/j.ejrad.2019.07.025.
[20]	IDILMAN IS, ANIKTAR H, IDILMAN R, et al. Hepatic steatosis: Quantification by proton density fat fraction with MR imaging versus liver biopsy[J]. Radiology, 2013, 267( 3): 767- 775. DOI: 10.1148/radiol.13121360.